Replimune Group, Inc. (Nasdaq: REPL) announced that the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE